Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy.
Eur Radiol. 2020 Aug;30(8):4234-4241. doi: 10.1007/s00330-020-06799-5. Epub 2020 Mar 31.
The loss of skeletal muscle mass is widely considered a predictor of poor survival and toxicity in breast cancer patients. The aim of this study is to evaluate if there is pectoralis muscle area (PMA) variation, reflecting loss of skeletal muscle mass, on consecutive MRI examinations after neoadjuvant chemotherapy.
The retrospective study protocol was approved by our institutional review board. A total of n = 110 consecutive patients (mean age 56 ± 11 years) who were treated with neoadjuvant chemotherapy (NAC) for histologically proven primary breast cancer between January 2017 and January 2019 and in whom tumor response was checked with standard breast MRI were included. Two radiologists calculated the pectoralis muscle cross-sectional area before and after NAC.
Time between the MRI examinations, before starting NAC and after completing NAC, was 166.8 ± 50 days. PMA calculated pre-NAC (8.14 cm) was larger than PMA calculated post-NAC (7.03 cm) (p < 0.001). According to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, there were no significant differences between responders (complete or partial response) and non-responders (p = 0.362). The multivariate regression analysis did not show any significant relationships between ΔPMA and age, time between MRI exams, estrogen and progesterone receptor status, human epidermal growth factor receptor status (HER-2), Ki-67 expression, lymph node status, RECIST criteria, histological type, average lesion size, molecular categories, and grade. Inter-reader (k = 0.72) and intra-reader agreement (0.69 and 0.71) in PMA assessment were good.
Pectoralis muscle mass varies in breast cancer patients undergoing NAC and this difference can be estimated directly on standard breast MRI.
• Pectoralis muscle area variation reflects loss of skeletal muscle mass. • Pectoralis muscle area on MRI is reduced after NAC. • Pectoralis muscle mass loss seems independent from other variables.
骨骼肌质量的丧失被广泛认为是乳腺癌患者生存和毒性不良的预测指标。本研究旨在评估新辅助化疗后连续 MRI 检查时是否存在胸大肌面积(PMA)变化,反映骨骼肌质量的丧失。
本回顾性研究方案获得了我们机构审查委员会的批准。共纳入 110 例连续患者(平均年龄 56±11 岁),这些患者于 2017 年 1 月至 2019 年 1 月期间因组织学证实的原发性乳腺癌接受新辅助化疗(NAC)治疗,且标准乳腺 MRI 检查显示肿瘤有反应。两位放射科医生在 NAC 前后计算胸大肌的横截面积。
MRI 检查之间的时间,即开始 NAC 前和完成 NAC 后,为 166.8±50 天。NAC 前计算的 PMA(8.14cm)大于 NAC 后计算的 PMA(7.03cm)(p<0.001)。根据实体瘤反应评估标准(RECIST)标准,应答者(完全或部分应答)与非应答者之间无显著差异(p=0.362)。多变量回归分析未显示 ΔPMA 与年龄、MRI 检查之间的时间、雌激素和孕激素受体状态、人表皮生长因子受体状态(HER-2)、Ki-67 表达、淋巴结状态、RECIST 标准、组织学类型、平均病变大小、分子分类和分级之间存在任何显著关系。在 PMA 评估中,读者间(k=0.72)和读者内一致性(0.69 和 0.71)良好。
接受 NAC 的乳腺癌患者的胸大肌质量发生变化,这种差异可以直接在标准乳腺 MRI 上估计。
•胸大肌面积变化反映骨骼肌质量的丧失。•NAC 后 MRI 上的胸大肌面积减少。•胸大肌质量损失似乎独立于其他变量。